by Team Small News | Nov 15, 2025 | Natco, Pharma
Natco Pharma, a leading Indian pharmaceutical company, has reported a decline in its net profit for the second quarter (Q2) of the current financial year. The company’s net profit stood at Rs 517.9 crore, which represents a decline of 23.44% compared to the same... by Team Small News | Nov 15, 2025 | Lupin, Pharma
Lupin Limited, a global pharmaceutical company, has achieved a significant milestone by securing an S&P Global ESG Score of 91 for 2025. This score places the company among a select group of pharmaceutical organizations that have crossed the 90-point threshold,... by Team Small News | Nov 12, 2025 | Aurobindo Pharma, Pharma
Motilal Oswal has recommended a “buy” rating for Aurobindo Pharma, with a target price of Rs 1350. The brokerage firm is optimistic about the company’s future prospects, driven by its strong product pipeline, increasing presence in the US market, and...
by Team Small News | Nov 12, 2025 | Glenmark, Pharma, Zydus
Zydus Lifesciences and Glenmark Pharmaceuticals have both received approvals from China’s National Medical Products Administration (NMPA) for their respective products. Zydus Lifesciences has been granted approval for Venlafaxine Extended-Release (ER) Capsules,... by Team Small News | Nov 12, 2025 | Cipla, Natco, Pharma
Cipla, Natco, Hetero, and Annora, four prominent Indian pharmaceutical companies, have secured significant contracts to supply generic drugs to China. This development marks a major breakthrough for Indian pharmaceutical companies in the Chinese market. The contracts...